- Home
- BMR vs UNCY Comparison
BMR vs UNCY Comparison
Compare BMR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- UNCY
- Stock Information
- Founded
- BMR 2009
- UNCY 2016
- Country
- BMR Israel
- UNCY United States
- Employees
- BMR N/A
- UNCY 14
- Industry
- BMR Computer Software: Prepackaged Software
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- BMR Technology
- UNCY Health Care
- Exchange
- BMR Nasdaq
- UNCY Nasdaq
- Market Cap
- BMR 59.3M
- UNCY 61.2M
- IPO Year
- BMR 2023
- UNCY 2021
- Fundamental
- Price
- BMR $2.10
- UNCY $0.51
- Analyst Decision
- BMR
- UNCY Strong Buy
- Analyst Count
- BMR 0
- UNCY 3
- Target Price
- BMR N/A
- UNCY $6.50
- AVG Volume (30 Days)
- BMR 103.9K
- UNCY 1.0M
- Earning Date
- BMR 04-15-2025
- UNCY 05-12-2025
- Dividend Yield
- BMR N/A
- UNCY N/A
- EPS Growth
- BMR N/A
- UNCY N/A
- EPS
- BMR N/A
- UNCY N/A
- Revenue
- BMR $3,064,000.00
- UNCY N/A
- Revenue This Year
- BMR N/A
- UNCY N/A
- Revenue Next Year
- BMR N/A
- UNCY $888.72
- P/E Ratio
- BMR N/A
- UNCY N/A
- Revenue Growth
- BMR 5.33
- UNCY N/A
- 52 Week Low
- BMR $2.12
- UNCY $0.20
- 52 Week High
- BMR $8.42
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- BMR 35.87
- UNCY 46.50
- Support Level
- BMR $2.12
- UNCY $0.53
- Resistance Level
- BMR $2.49
- UNCY $0.61
- Average True Range (ATR)
- BMR 0.19
- UNCY 0.06
- MACD
- BMR 0.01
- UNCY -0.01
- Stochastic Oscillator
- BMR 3.09
- UNCY 25.75
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.